Navigation Links
Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
Date:5/14/2009

Technology to improve accuracy of ovarian cancer diagnosis

TAMPA, Fla., May 14 /PRNewswire/ -- Moffitt Cancer Center and Frantz BioMarkers, LLC have signed a license agreement on phospholipid biomarkers of ovarian cancer. Frantz BioMarkers, which has been granted exclusive worldwide rights to Moffitt's interests in the biomarkers, will pay initiation, developmental milestone and license maintenance fees, and royalties on sales. Moffitt and Frantz BioMarkers will collaborate on ovarian cancer biomarker research, combining use of these licensed markers with lipid markers developed independently by Frantz BioMarkers.

Each year, 26,000 women in the United States are diagnosed with ovarian cancer, and 16,000 die of the disease. There is no effective screening tool or method for accurate diagnosis without surgery. Even among symptomatic women, surgery is the only reliable way to distinguish between benign and malignant disease. It is estimated that up to 5 percent of women in the United States will undergo surgery for a suspected ovarian neoplasm. More than two-thirds of women undergoing surgery for suspected ovarian malignancy do not have cancer.

The only clinical blood biomarker available for diagnosis is CA125, which is unreliable, especially for accurate diagnosis at an early stage when a cure is feasible. Researchers at Moffitt and Frantz BioMarkers discovered that when CA125 is combined with selected phospholipids, the diagnostic accuracy for early stage ovarian cancer can significantly improve. More than 2,200 women donated blood samples for the research through the Tampa Bay Ovarian Cancer Coalition, a collaborative regional network. Frantz BioMarkers is developing these biomarkers into a clinical diagnostic test.

Co-inventors of the technology
'/>"/>

SOURCE Moffitt Cancer Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CMC, Moffitt Partner to Study Cancer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
10. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/27/2014)... , July 27, 2014 /PRNewswire-iReach/ -- ... survey on Global and Chinese Vardenafil (CAS ... basic information of Vardenafil (CAS 224785-90-4) including ... report then explores global and China,s top ... product specification, capacity, production value, cost, gross ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4
... /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ... traded biopharmaceutical company developing human vaccines for diseases ... infectious agents, announced today that Chuck Panozzo, founder ... joined the GeoVax Labs awareness campaign as an ...
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting ... hospital days during the first year after treatment compared ...
Cached Medicine Technology:Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5
(Date:7/27/2014)... Zensah®, the leader in compression technology and sports medicine, has ... . The wrist support features an adjustable velcro strap and ... Epicondylitis, more commonly referred to as tennis elbow and golfers ... the tendons attached to the outside of the elbow. Although ... work the wrist and fingers turn into a tendon that ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Manufacturers of ... with organic ways to achieve a younger appearance. The ... buyer's guide to help men and women explore the ... The details that are presented in the posted guide ... price information for consumers. On drawback to some natural ...
(Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The ... (GFRP) Composites Market By Raw Material, By Manufacturing ... & Others) & By Geography – Global Trends ... global GFRP Composites market with an analysis and ... market data tables and 107 figures spread through ...
(Date:7/27/2014)... from The University of Manchester have discovered why medication to ... published in Nature Medicine , show that drugs widely ... , In the UK pneumonia, which is caused ... year and is more serious for babies, young children, the ... , More than 5 million people in the UK are ...
Breaking Medicine News(10 mins):Health News:Zensah® Releases New Wrist Support 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2
... good judges of affordability, but a new study reveals that ... you think about a larger pool of resources (such as ... your wallet). Through a series of four experiments, researchers ... time. Counting calories" Youre more likely to eat that slice ...
... from the University of California San Francisco has identified ... woman is likely to develop subsequent invasive cancer after ... cancer. The research, published by Cell Press in the ... can be used to determine whether a woman should ...
... GREEN BAY, Wis., Nov. 12 Shopko announced ... position of President and Chief,Merchandising Officer. Jones will ... marketing activities of the regional mass retailer. ... roles in the,department store sector, mid-tier chain stores ...
... Va., Nov. 12 Conservationists and scientists,from around ... and Research Symposium, in Orlando, Florida. The Symposium ... Bailey Center for Elephant,Conservation(R) and the International Elephant ... two day global Conference on Elephant,Tuberculosis Research. The ...
... Health releases nationwide eValue8,findings, SCOTTSDALE, Ariz., ... report of health plan performance released today ... (NBCH), health plans could do a,better job ... enabling,improvements in patient safety, care coordination, consumer ...
... Hazelden Foundation offers Barry McMillen - Nicotine Cessation Expert and ... ... Nov. 12 Using tobacco isn,t just a,habit; it,s an addiction. ... for over 50 years. The same principles,of the Hazelden treatment experience ...
Cached Medicine News:Health News:Big ticket: You'll spend more thinking about your bank account than about your wallet 2Health News:Biomarkers predict risk for invasive breast cancer years before the tumor develops 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 3Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 4Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2
... The Wound Care Manager ... for patient assessment and data ... care. This application was developed ... Wound Care along with the ...
... specifically for the Palm Organizers to ... rounds. It is intended to record ... that are requested by the senior ... round examinations and to record the ...
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Medicine Products: